Han Chiu
About Han Chiu
Han Chiu is the Chief Technology Officer at Syneos Health with expertise in developing prescription digital therapeutics and conducting decentralized clinical trials.
Chief Technology Officer at Syneos Health
Han Chiu holds the position of Chief Technology Officer at Syneos Health. In this role, he is responsible for overseeing the technological advancements and strategies within the organization. His leadership drives the integration of innovative digital solutions in healthcare, enhancing the company's ability to conduct cutting-edge research and deliver effective patient-centered care.
Expertise in Developing Prescription Digital Therapeutics
Han Chiu is recognized for his expertise in developing prescription digital therapeutics. He has played a pivotal role in the creation and deployment of digital tools aimed at treating various medical conditions. His work includes the development of CT-155, a digital therapeutic designed for schizophrenia, and the Rejoyn™ platform for Major Depressive Disorder. His contributions have significantly advanced the field of digital health solutions.
Involvement in Remote and Decentralized Clinical Trials
Han Chiu has extensive experience in conducting fully remote and decentralized clinical trials. These trials leverage digital tools to facilitate the participation of subjects without the need for physical site visits. His involvement in studies such as the ReMMi-D pivotal study for migraine treatment and the CONVOKE study for schizophrenia treatment demonstrates his commitment to utilizing technology to improve clinical trial efficiency and accessibility.
Background in Cognitive and Neurobehavioral Mechanisms
Han Chiu's background in cognitive and neurobehavioral mechanisms informs his work in digital therapeutics. His understanding of these mechanisms enables him to create effective digital solutions that target specific neurological and behavioral conditions. This scientific grounding supports his contributions to platforms like Clickotine®, a digital therapeutic aimed at smoking cessation, which focuses on modifying behavior and aiding users in quitting smoking.
Collaboration with Pharmaceutical Companies
Han Chiu has a history of collaborating with major pharmaceutical companies, including Boehringer Ingelheim. These partnerships involve the development and implementation of digital therapeutics and clinical trial innovations. His ability to work alongside pharmaceutical giants highlights his influence and the impact of his technological expertise on the pharmaceutical industry's approach to patient care and treatment development.